Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis

Table 2 Detailed information of the administration drug, dose and timing of administration

Ref.	Drug	Dose	Route	Timing of administration
Jespersen et al[32], 2019	Teriparatide	20 μg	Subcutaneous	90 d
Sheng et al[37], 2018	Zoledronic acid	5 mg	Intravenous	Intravenous single dose 3 d after surgery
Ide et al[31], 2018	Teriparatide + denosumab	60 mg	Subcutaneously	Administered at 2 and 8 mo following surgery
	Teriparatide	20 μg	Subcutaneous	Administered froma month before surgery to 12 mo after surgery
Seki et al[36], 2017	Teriparatide	20 μg	Subcutaneous	Once a day starting 3 mo before surgery through 21 mo after surgery
Ebata et al[30], 2017	Teriparatide	56.5 μg	Subcutaneous	Once a week starting, 1 wk after surgery for a total of 6 mo
Cho et al[29], 2017	Teriparatide
Yagi et al[39], 2016	Teriparatide	20 μg	Subcutaneous	Once a day from the day of surgery for a total of 18 mo
Chen et al[28], 2016	zoledronic acid	5 mg	Intravenous	Single dose 3 d after surgery
Ohtori et al[35], 2013	Teriparatide/Risedronate	20 μg	Subcutaneous	Once a day starting 2 mo before surgery through 10 mo after surgery
		2.5 mg	Oral	Once a day starting 2 mo before surgery through 10 mo after surgery
Li et al[33], 2012	Zoledronic acid	5 mg	Intravenous	3 d after the surgery
Nagahama et al[34], 2011	Alendronate	35 mg	Oral	Not specified
Wang et al[40], 2021	Teriparatide	20 μg	Subcutaneously	Once daily and continuously for more than 6 mo starting from 1 d after surgery
	Zoledronic acid	5 mg	Intravenously	15 min to 3 d after surgery